Compare VBNK & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | VBNK | CTNM |
|---|---|---|
| Founded | 1980 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.0M | 575.3M |
| IPO Year | 2021 | 2024 |
| Metric | VBNK | CTNM |
|---|---|---|
| Price | $16.33 | $14.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $13.00 | ★ $18.60 |
| AVG Volume (30 Days) | 42.3K | ★ 251.6K |
| Earning Date | 03-04-2026 | 03-05-2026 |
| Dividend Yield | ★ 0.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $85,792,576.00 | N/A |
| Revenue This Year | $37.01 | N/A |
| Revenue Next Year | $30.71 | N/A |
| P/E Ratio | $25.63 | ★ N/A |
| Revenue Growth | ★ 7.44 | N/A |
| 52 Week Low | $8.51 | $3.35 |
| 52 Week High | $16.99 | $16.01 |
| Indicator | VBNK | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 56.77 | 62.68 |
| Support Level | $15.88 | $14.59 |
| Resistance Level | $16.99 | $16.01 |
| Average True Range (ATR) | 0.37 | 1.09 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 41.14 | 68.40 |
VersaBank is a Schedule I Canadian bank that provides mainly commercial lending and banking services to select niche markets in Canada and the United States. Its products and services include credit assets, deposits, and cybersecurity services through its wholly owned subsidiary. The bank operates through four segments: Digital Banking Canada and Digital Banking USA, both using a business-to-business model with proprietary financial technology to serve underserved markets; DRTC, which provides cybersecurity services and banking and financial technology development; and Digital Meteor, which owns proprietary technology supporting next-generation digital assets, including Real Bank Deposit Tokens (RBDTs). The majority of revenue comes from Digital Banking.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.